What's Happening?
Augurex Life Sciences Corp. has been awarded the Immunology Abstract Award at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Conference. The award recognizes the company's research on anti-14-3-3eta autoantibodies, a novel biomarker
that distinguishes axial spondyloarthritis from mechanical back pain. This research addresses a significant unmet need in diagnosing inflammatory back pain. The abstract was selected from 800 submissions and will be featured in an ePoster discussion, highlighting its potential impact on clinical practice and laboratory medicine.
Why It's Important?
This recognition underscores the importance of developing precise diagnostic tools in the medical field, particularly for conditions like axial spondyloarthritis, which are often misdiagnosed. The ability to accurately differentiate between inflammatory and mechanical back pain can lead to more effective treatments and improved patient outcomes. Augurex's work exemplifies the critical role of innovation in healthcare diagnostics, potentially influencing future research and development in the field.
What's Next?
Dr. Anthony Marotta, the lead researcher, will receive the award at the ADLM IID Division Awards Reception and present the findings during an ePoster discussion. Augurex will also showcase its SPINEstat® diagnostic assay at the ADLM Clinical Lab Expo, where it is a finalist for the Disruptive Technology Award. These events will provide further opportunities for engagement with the diagnostics community and potential collaborations.
